Nigella Sativa Supplementation in Hyperlipidemia Treatment

NCT ID: NCT06890546

Last Updated: 2025-03-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 64 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-06-01
• Study Completion Date: 2025-02-28

Brief Summary

Hyperlipidemia is defined as an elevation of plasma cholesterol, lipid, or lipoprotein levels above normal due to abnormal fat metabolism or function, and individuals with hyperlipidemia are approximately twice as likely to develop cardiovascular disease. The first approach to treating hyperlipidemia is lifestyle changes, including dietary therapy and physical activity. In addition to traditional methods, treatments also include pharmacological interventions, and research on natural products and complementary therapies is increasing to increase the effectiveness of these treatment approaches. In this context, Nigella Sativa (NS) oil has emerged as a promising natural option in the treatment of hyperlipidemia and obesity in recent years.

The aim of this study was to examine the effects of NS oil supplementation given together with dietary intervention in individuals diagnosed with mild obesity.

The main questions it aims to answer are:

• Does Nigella Sativa supplementation improve blood lipid profiles in overweight or obese individuals?
• Does Nigella Sativa supplementation improve body composition in overweight or obese individuals?

Participants were individuals who were diagnosed with hyperlipidemia according to American Heart Association criteria as a result of medical evaluation by a cardiologist and who were deemed appropriate to use black seed oil supplements. Those who volunteered to participate in the study were included in the study.

The researchers are examining whether there is any effect on biochemical and anthropometric parameters by giving Nigella Sativa supplementation to a group in addition to a low-calorie diet for eight weeks.

Detailed Description

This research, which is a randomized controlled intervention study, was conducted between June 2023 and February 2024 with adult individuals with a BMI>25 kg/m2 who applied to the Cardiology Polyclinic of Karamürsel State Hospital and were referred to a nutrition and diet specialist after being diagnosed with hyperlipidemia according to AHA criteria by the physician.

Sample Selection and Randomization The sample size of the study was calculated using the G-Power 3.1.9 analysis program with a medium effect size (d=0.60), 90% power, α: 0.05 and 1-β: 0.95, with a minimum of 32 people in each group, 64 people were included. The 64 people who met the inclusion criteria were assigned to the intervention (n=32) and control (n=32) groups using the block randomization method, with similar age and gender.

Inclusion Criteria from the Study Individuals who were diagnosed with hyperlipidemia between the ages of 18-65, who did not have any serious comorbidities (kidney, liver and immune deficiency, oncological and psychiatric diseases), who were not pregnant or breastfeeding, who did not take any nutritional supplements including black seed, who did not have a known history of allergy to black seed and its products, who did not use medications that could interact with black seed oil (anticoagulant, antihypertensive, etc.), who did not use antilipidemic or anticholesterolemic medications, who did not do heavy exercise, who did not consume alcohol regularly and who did not have any special diet requirements were included in the study.

Data Collection Tools Research data were recorded using a questionnaire form, anthropometric measurements, biochemical tests and the IPAQ form.

Survey Form: Sociodemographic information, smoking and nutritional habits of the participants were recorded in the survey form.

Anthropometric Measurements: At the beginning and end of the study, body weights and analyses were performed using a bioelectrical impedance (BIA) device (Tanita Perfecto) with a sensitivity of 50 grams in accordance with the measurement standards. According to the BIA analysis, fat ratio (%), fat mass, fat-free mass, muscle mass and total body water were evaluated. At the beginning and end of the study, waist, hip and neck circumferences were measured with a non-stretchable tape measure, paying attention to anthropometric measurement standards. Waist/height and waist/hip values were calculated. Height (cm) was measured with a stadiometer in the Frankfort plane, standing and with the head upright. The body mass index (BMI) of the participants was calculated according to the body weight (kg) / height (m)2 formula and classified according to the World Health Organization (WHO) criteria.

International Physical Activity Questionnaire Short Form (IPAQ): IPAQ-Short form, developed by Craig et al. and whose Turkish validity and reliability study was conducted by Öztürk, was used to assess the physical activity levels of the participants. Physical activity levels were classified as light, moderate and vigorous active.

Biochemical Tests: Participants' biochemical tests (total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride, fasting blood glucose, ALT and AST) were analyzed in the hospital biochemistry laboratory using routine methods at the beginning and end of the study from blood samples taken by a nurse after at least 12 hours of fasting and without consuming alcohol for 24 hours before.

Research Plan In this study, 64 hyperlipidemic individuals with BMI>25 kg/m2 were divided into 2 groups as control (n=32 individuals) and intervention (n=32 individuals). The control group was given a low-fat, low-cholesterol weight loss diet specific to the individual for 8 weeks, while the intervention group (n=32) was given a similar diet along with 2x900 mg black seed oil in softgels. Questions regarding the participants' sociodemographic characteristics, smoking, alcohol consumption and physical activity habits were recorded on a questionnaire form through face-to-face interviews. Participants attended face-to-face dietician control interviews every two weeks to observe compliance with the nutrition programs throughout the study.

Diet Plan: While determining the daily energy needs of the participants, the resting metabolic rate was calculated with the Mifflin-St.Jeor formula. The physical activity levels of the individuals were determined using the IPAQ-Short Form. The thermic effect of the nutrients was taken as 10% and the total daily energy requirement was calculated. In order for the participants to lose weight, 500 calories were subtracted from the total energy requirement. A nutrition program was given in accordance with the diet recommendations created by the American Heart Association (AHA) for hyperlipidemic individuals.

Black seed oil: In this study, black seed oil in the form of 900 mg softgels was administered orally to the intervention group at a dose of 2x900 mg. Black seed oil obtained by the cold-pressing method (TAB İlaç Sanayi A.Ş., Esenyurt, İstanbul) is in softgel form. The product is a licensed supplement with the TR-34-K-210340 certificate by the Turkish Standards Institute (TSE) and the Food Supplement Approval Number 003683-21.12.2017 of the Ministry of Agriculture and Forestry. Some studies investigating the effects of black seed oil on hyperlipidemia and other health problems show that 1-2 g of black seed or 500-1000 mg of black seed oil per day may be effective. These doses are usually taken in two divided doses daily. Moreover, a daily therapeutic dose of 2000 mg N.S has been considered safe in previous studies. Human and animal models showed no serious side effects or toxicological effects caused by the plant. The black seed oil capsules given to the participants were provided by the researcher.

Conditions

Hyperlipidaemia; Hyperlipidemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Nigella Sativa Group

Nigella Sativa oil supplement and low calorie diet intervention

Group Type: EXPERIMENTAL

Nigella Sativa Oil capsule

Intervention Type: DIETARY_SUPPLEMENT

8 weeks 2 x 900 mg Nigella Sativa oil capsule daily

Diet

Intervention Type: BEHAVIORAL

Low calorie diet intervention

Control Group

low calorie diet intervention

Group Type: PLACEBO_COMPARATOR

Diet

Intervention Type: BEHAVIORAL

Low calorie diet intervention

Interventions

Nigella Sativa Oil capsule

8 weeks 2 x 900 mg Nigella Sativa oil capsule daily

Intervention Type: DIETARY_SUPPLEMENT

Diet

Low calorie diet intervention

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Adults individuals who were diagnosed hyperlipidemia
• Individuals suitable for taking Nigella satvia supplement
• Individuals BMI>25 kg/m2

Exclusion Criteria

• Chronic liver disease,
• Chronic kidney disease,
• Heart failure, infarction or cerebrovascular disease,
• Pregnant and breastfeeding women,
• Severe psychiatric disorders,
• Oncological diseases,
• Individuals using medications that could interact with black seed oil (anticoagulant, antihypertensive, etc.)
• Individuals using antilipidemic or anticholesterolemic medications
• Individuals did not do heavy exercise
• Individuals using any nutritional supplement
• Individuals have a known history of allergy
• Individuals did not consume alcohol regularly
• Individuals with special dietary needs

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Istanbul Bilgi University

OTHER

Sponsor Role: lead

Responsible Party

Hande Seven Avuk

Head of Nutrition and Dietetics Department

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Hande Seven Avuk, PhD

Role: PRINCIPAL_INVESTIGATOR

İstanbul Bilgi University

Locations

İstanbul Bilgi University

Istanbul, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

References

Adanir SS, Kervancioglu P, Bahsi I, Al Saadi M, Van de Heyning P, Topsakal V. Anatomical investigation of safety determining factors for keyhole drilling trajectories for robotic cochlear implant surgery. Eur Arch Otorhinolaryngol. 2025 Jun;282(6):3037-3050. doi: 10.1007/s00405-024-09198-4. Epub 2025 Jan 17.

Reference Type: BACKGROUND

PMID: 39825202 (View on PubMed)

Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO. A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr. 1990 Feb;51(2):241-7. doi: 10.1093/ajcn/51.2.241.

Reference Type: BACKGROUND

PMID: 2305711 (View on PubMed)

Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. doi: 10.1249/01.MSS.0000078924.61453.FB.

Reference Type: BACKGROUND

PMID: 12900694 (View on PubMed)

Norgan NG. Laboratory and field measurements of body composition. Public Health Nutr. 2005 Oct;8(7A):1108-22. doi: 10.1079/phn2005799.

Reference Type: BACKGROUND

PMID: 16277823 (View on PubMed)

Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007 May;39(2):175-91. doi: 10.3758/bf03193146.

Reference Type: BACKGROUND

PMID: 17695343 (View on PubMed)

Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018 Mar 20;137(12):e67-e492. doi: 10.1161/CIR.0000000000000558. Epub 2018 Jan 31. No abstract available.

Reference Type: BACKGROUND

PMID: 29386200 (View on PubMed)

Al Asoom L. Is Nigella sativa an Effective Bodyweight Lowering Agent and a Mitigator of Obesity Risk? A Literature Review. Vasc Health Risk Manag. 2022 Jul 12;18:495-505. doi: 10.2147/VHRM.S373702. eCollection 2022.

Reference Type: BACKGROUND

PMID: 35855753 (View on PubMed)

Sahebkar A, Beccuti G, Simental-Mendia LE, Nobili V, Bo S. Nigella sativa (black seed) effects on plasma lipid concentrations in humans: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2016 Apr;106:37-50. doi: 10.1016/j.phrs.2016.02.008. Epub 2016 Feb 10.

Reference Type: BACKGROUND

PMID: 26875640 (View on PubMed)

Rounagh M, Musazadeh V, Hosseininejad-Mohebati A, Falahatzadeh M, Kavyani Z, Rostami RB, Vajdi M. Effects of Nigella sativa supplementation on lipid profiles in adults: An updated systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2024 Jun;61:168-180. doi: 10.1016/j.clnesp.2024.03.020. Epub 2024 Mar 22.

Reference Type: BACKGROUND

PMID: 38777430 (View on PubMed)

Lichtenstein AH, Appel LJ, Vadiveloo M, Hu FB, Kris-Etherton PM, Rebholz CM, Sacks FM, Thorndike AN, Van Horn L, Wylie-Rosett J. 2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. 2021 Dec 7;144(23):e472-e487. doi: 10.1161/CIR.0000000000001031. Epub 2021 Nov 2.

Reference Type: BACKGROUND

PMID: 34724806 (View on PubMed)

Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care. 2017 Jun;23(9 Suppl):S139-S148.

Reference Type: BACKGROUND

PMID: 28978219 (View on PubMed)

Kaatabi H, Bamosa AO, Lebda FM, Al Elq AH, Al-Sultan AI. Favorable impact of Nigella sativa seeds on lipid profile in type 2 diabetic patients. J Family Community Med. 2012 Sep;19(3):155-61. doi: 10.4103/2230-8229.102311.

Reference Type: BACKGROUND

PMID: 23230380 (View on PubMed)

Razmpoosh E, Safi S, Nadjarzadeh A, Fallahzadeh H, Abdollahi N, Mazaheri M, Nazari M, Salehi-Abargouei A. The effect of Nigella sativa supplementation on cardiovascular risk factors in obese and overweight women: a crossover, double-blind, placebo-controlled randomized clinical trial. Eur J Nutr. 2021 Jun;60(4):1863-1874. doi: 10.1007/s00394-020-02374-2. Epub 2020 Sep 2.

Reference Type: BACKGROUND

PMID: 32876804 (View on PubMed)

Ibrahim RM, Hamdan NS, Mahmud R, Imam MU, Saini SM, Rashid SN, Abd Ghafar SA, Latiff LA, Ismail M. A randomised controlled trial on hypolipidemic effects of Nigella Sativa seeds powder in menopausal women. J Transl Med. 2014 Mar 31;12:82. doi: 10.1186/1479-5876-12-82.

Reference Type: BACKGROUND

PMID: 24685020 (View on PubMed)

Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, Damanhouri ZA, Anwar F. A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pac J Trop Biomed. 2013 May;3(5):337-52. doi: 10.1016/S2221-1691(13)60075-1.

Reference Type: BACKGROUND

PMID: 23646296 (View on PubMed)

Qidwai W, Hamza HB, Qureshi R, Gilani A. Effectiveness, safety, and tolerability of powdered Nigella sativa (kalonji) seed in capsules on serum lipid levels, blood sugar, blood pressure, and body weight in adults: results of a randomized, double-blind controlled trial. J Altern Complement Med. 2009 Jun;15(6):639-44. doi: 10.1089/acm.2008.0367.

Reference Type: BACKGROUND

PMID: 19500003 (View on PubMed)

Mahdavi R, Namazi N, Alizadeh M, Farajnia S. Effects of Nigella sativa oil with a low-calorie diet on cardiometabolic risk factors in obese women: a randomized controlled clinical trial. Food Funct. 2015 Jun;6(6):2041-8. doi: 10.1039/c5fo00316d.

Reference Type: BACKGROUND

PMID: 26029855 (View on PubMed)

Heshmati J, Namazi N. Effects of black seed (Nigella sativa) on metabolic parameters in diabetes mellitus: a systematic review. Complement Ther Med. 2015 Apr;23(2):275-82. doi: 10.1016/j.ctim.2015.01.013. Epub 2015 Feb 9.

Reference Type: BACKGROUND

PMID: 25847566 (View on PubMed)

Zaoui A, Cherrah Y, Alaoui K, Mahassine N, Amarouch H, Hassar M. Effects of Nigella sativa fixed oil on blood homeostasis in rat. J Ethnopharmacol. 2002 Jan;79(1):23-6. doi: 10.1016/s0378-8741(01)00342-7.

Reference Type: BACKGROUND

PMID: 11744291 (View on PubMed)

Meddah B, Ducroc R, El Abbes Faouzi M, Eto B, Mahraoui L, Benhaddou-Andaloussi A, Martineau LC, Cherrah Y, Haddad PS. Nigella sativa inhibits intestinal glucose absorption and improves glucose tolerance in rats. J Ethnopharmacol. 2009 Jan 30;121(3):419-24. doi: 10.1016/j.jep.2008.10.040. Epub 2008 Nov 17.

Reference Type: BACKGROUND

PMID: 19061948 (View on PubMed)

Datau EA, Wardhana, Surachmanto EE, Pandelaki K, Langi JA, Fias. Efficacy of Nigella sativa on serum free testosterone and metabolic disturbances in central obese male. Acta Med Indones. 2010 Jul;42(3):130-4.

Reference Type: BACKGROUND

PMID: 20724766 (View on PubMed)

Other Identifiers

NSHYPERLIPIDEMIA

Identifier Type: -

Identifier Source: org_study_id